-
No.210
この特許のこと? PCT/J…
2016/09/22 17:48
>>No. 180
この特許のこと?
PCT/JP2012/060099; 2012. 04. 13公開
WO/2012/141280; 2012. 10. 18公開
発明の名称:DNAワクチン
発明の要約:本発明は、生活習慣病関連因子の特異的エピトープを含むアミノ酸配列が挿入されたキメラB型肝炎ウイルスコア抗原ポリペプチドをコードする発現ベクターを含む、当該生活習慣病の治療又は改善剤であって、該特異的エピトープを含むアミノ酸配列が、B型肝炎ウイルスコア抗原ポリペプチドのアミノ酸残基80と81の間に挿入されている、治療又は改善剤を提供するものである。
[実施例1] まとめ
以上、血圧測定および抗体価測定の結果から、HBc-AngII ISS(+)DNAワクチン投与により、AngIIに対する抗体価を上昇させ、高血圧症を予防又は治療し得ることが示された。 -
No.1231
コピペだけでなく、図書館かPC…
2016/09/16 23:13
コピペだけでなく、図書館かPCで実際に特許公報も閲覧下さい:
投与経路は、
実施例[0034] 慢性炎症の完成した7日目から前記3層シームレスソフトカプセルの大腸内投与(経肛門)を開始した。 -
No.1225
会社の都合により国際出願せずに…
2016/09/16 22:50
会社の都合により国際出願せずに
日本国内出願に留めていると思われる特許の優劣を議論する気は
毛頭ありませんが
>>その結果、デコイ治療群は用量依存的に有意な生存率の改善を認め(図4)、
上記の明細書には「有意な生存率の改善」と記載されていますが、
実施例には各群に供したネズミの匹数が記載されていません。
また、どのような有意差検定が行われたのかの記載もなく、
明細書の結論には「有意な生存率の改善」と記されています。
投与経路は、
[0034] 慢性炎症の完成した7日目から前記3層シームレスソフトカプセルの大腸内投与(経肛門)を開始した。
下記の委託研究の締切に合わせ無理な出願でしたのでしょうか。
(出願人による申告)平成22年度、経済産業省、補正予算事業地域イノベーション創出研究開発事業「核酸含有PLGAナノ粒子技術を用いた経口DDS製剤の研究開発」再委託研究、産業技術力強化法第19条の適用を受ける特許出願 -
No.1062
今回成立した特許(出願日:20…
2016/09/16 12:12
今回成立した特許(出願日:2012. 08. 13)は、
2014. 02. 27に公開されていますが(JP2014037358)、
PCT(特許協力条約)に基づいた国際出願ではありません。
出願時に国外にも日本と同様に直接出願している可能性はありますが、
国外での特許権利化を放棄し、
日本国内のみの成立で良しと判断したのではないでしょうか。 -
No.587
ArQule Presents…
2016/07/02 11:43
ArQule Presents Preliminary Clinical Data for ARQ 087 Demonstrating Evidence of Anticancer Activity in Intrahepatic Cholangiocarcinoma at the ESMO 18th World Congress on Gastrointestinal Cancer
Jun 30, 2016
75% disease control rate, including a 25% objective response rate, was observed in 12 evaluable patients harboring FGFR2 genetic alterations
http://investors.arqule.com/releasedetail.cfm?ReleaseID=977747 -
No.469
Charleston Labo…
2016/06/14 09:11
Charleston Laboratories And Daiichi Sankyo Announce FDA Acceptance Of New Drug Application (NDA) For CL-108
6/13/2016
http://charlestonlabs.com/wp-content/uploads/2016/06/CL-108-NDA-Acceptance-Release-FINAL-6-12-161.pdf -
No.626
大日本住友製薬:ニュースリリー…
2016/06/13 14:32
大日本住友製薬:ニュースリリース 2016.06.07
ボストン・バイオメディカルのウェブサイトに、米国臨床腫瘍学会(ASCO)で発表したnapabucasin(BBI608)およびamcasertib(BBI503)に関するポスター資料を掲載しました
http://www.bostonbiomedical.com/research-and-development/publications/ -
No.554
Intercept Pharm…
2016/06/01 13:13
Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT)の
Press releases (May 31 at 8:30 a.m. ET) がありました。
http://ir.interceptpharma.com/releasedetail.cfm?ReleaseID=973265 -
No.864
Daiichi Sankyo …
2016/03/23 13:36
Daiichi Sankyo and ArQule Announce Continuation of METIV-HCC Phase 3 Study of Tivantinib (ARQ 197) in Second-Line Hepatocellular Carcinoma
BURLINGTON, Mass. and PARSIPPANY, N.J., March 22, 2016 (GLOBE NEWSWIRE) -- ArQule, Inc. (Nasdaq:ARQL) and Daiichi Sankyo today announced that the independent data monitoring committee (DMC) of the METIV-HCC study conducted the planned interim assessment and it was determined the trial will continue to its final analysis.
http://files.shareholder.com/downloads/ARQL/1155639440x0x882287/84DDD033-9DCA-46B6-9556-D4E90448754B/METIV-HCC_Interim_Analysis_Press_Release__cs.pdf -
No.673 強く買いたい
BioInvent recei…
2016/03/01 08:55
BioInvent receives €2 million milestone payment from Daiichi Sankyo for licensed n-CoDeR® antibody progressing into Phase I clinical trial
Lund, Sweden – 29 February 2016 – BioInvent International (BINV) today announced that it will receive a €2 million milestone payment under the collaboration with Daiichi Sankyo pertaining to the progression of an anti-FGFR4 antibody into a Phase I clinical trial in the EU.
http://www.bioinvent.se/media-centre/press-releases/release/?ReleaseID=0343D46385679286 -
No.358
ArQule Provides…
2016/01/28 23:56
ArQule Provides Proprietary Pipeline Update for AKT Inhibitors
#First cohort dosed in phase 1 trial with ARQ 092 in Proteus syndrome
#ArQule receives Investigational New Drug approval for ARQ 751
BURLINGTON, Mass., Jan. 28, 2016 (GLOBE NEWSWIRE) -- ArQule, Inc. (NASDAQ:ARQL) today announced a pipeline update for its AKT inhibitors, including ARQ 092 and ARQ 751, both orally available, selective pan-AKT inhibitors.
http://investors.arqule.com/releasedetail.cfm?ReleaseID=952158 -
No.356
ArQule Presents…
2016/01/28 16:31
ArQule Presents Clinical Biomarker Data From Phase 2 Study and Ongoing Phase 3 METIV-HCC Study of Tivantinib in Second-Line Hepatocellular Carcinoma at the 2016 Gastrointestinal Cancers Symposium
Preliminary analysis of baseline MET incidence in METIV-HCC trial confirms results observed in phase 2 trial
BURLINGTON, Mass., Jan. 25, 2016 (GLOBE NEWSWIRE) -- ArQule, Inc. (NASDAQ:ARQL) today announced that an analysis of preliminary baseline tumor MET status of patients screened in the phase 3 METIV-HCC trial for tivantinib in second-line hepatocellular carcinoma (HCC) confirms previously presented data from the company's phase 2 trial in the same patient population. In both trials MET status, as determined by immunohistochemistry, was more frequently high after first-line therapy and was a predictive and prognostic biomarker in the phase 2 trial. The data was presented in an oral presentation and poster at the 2016 Gastrointestinal Cancers Symposium (ASCO GI) on January 22, 2016.
http://investors.arqule.com/releasedetail.cfm?ReleaseID=951459 -
No.51
Daiichi Sankyo …
2015/12/29 11:06
Daiichi Sankyo Korea Signs Agreement with Daewoong Pharmaceutical for the Co-promotion of LIXIANA® in South Korea
Tokyo, Japan (December 28, 2015) – Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced that its wholly owned subsidiary, Daiichi Sankyo Korea Co., Ltd. (hereafter “DSKR;” headquarters: Jongno-gu, Seoul, South Korea), and Daewoong Pharmaceutical Co., Ltd. (hereafter “Daewoong Pharmaceutical;” headquarter: Gangnam-gu, Seoul, South Korea) have signed an agreement for the co-promotion of the oral, once-daily anti-coagulant, LIXIANA® (generic name: edoxaban).
http://www.daiichisankyo.com/media_investors/media_relations/press_releases/detail/006390.html -
No.45
Daiichi Sankyo …
2015/12/29 10:34
Daiichi Sankyo Layoffs Begin in Texas as Company Implements Restructuring Plan
December 28, 2015
By Alex Keown, BioSpace.com Breaking News Staff
PARSIPPANY, N.J., -- Pink slips have begun to arrive for Daiichi Sankyo, Inc., employees as the company undergoes a restructuring of its sales force in the United States. This week 18 Texas-based sales team members received layoff notifications, the Dallas Business Journal reported this morning.
http://www.bizjournals.com/dallas/news/2015/12/22/japanese-pharmaceutical-company-to-lay-off-16.html -
No.851
ArQule and Daii…
2015/12/12 09:37
ArQule and Daiichi Sankyo Announce Completion of Accrual in METIV-HCC Phase 3 Trial of Tivantinib for Second-Line Hepatocellular Carcinoma
Planned interim analysis expected to occur early in the second quarter of 2016
BURLINGTON, MA and PARSIPPANY, NJ, USA I December 10, 2015 I ArQule, Inc. (Nasdaq:ARQL) and Daiichi Sankyo, Inc. today announced that the phase 3 METIV-HCC trial for tivantinib in second-line hepatocellular carcinoma (HCC) has completed accrual. In addition, the planned interim analysis, which is triggered when 60 percent of events occur, is expected to take place early in the second quarter of 2016.
http://files.shareholder.com/downloads/ARQL/1155639440x0x865961/0D8A6C98-9982-4F61-B589-681EB1A3E15E/METIV-HCC_Complete_Recruitment_-_US_-_FINAL.pdf -
No.840
>>現状の適用範囲内で副作用等…
2015/12/10 23:17
>>現状の適用範囲内で副作用等ネガティブ情報が入ってきた場合の方がよっぽど怖い!
クロピドグレル、全世界で長期間使用されているP2Y12受容体阻害薬。
その初期活性代謝物、プラスグレルに、
現在の適応症使用に何の懸念があると思っているのですか。
予期せぬ副作用とかでは、医薬品OBとしての答えにはなりませんよ。 -
No.796
Sorry, BAD REPO…
2015/12/08 23:41
Sorry, BAD REPORT:
Anti-platelet therapy (Prasugrel, Effient®) does not significantly reduce pain crises in sickle cell disease
Dana-Farber Cancer Institute
BOSTON, MA, and OAKLAND, CA (Dec. 8, 2015) - Treatment with the antiplatelet agent prasugrel does not significantly reduce the rate of pain crises or severe lung complications in children with sickle cell disease, according to a report published in the New England Journal of Medicine describing one of the largest and most geographically diverse international clinical trials on sickle cell disease to date.
http://www.eurekalert.org/pub_releases/2015-12/dci-atd120315.php -
No.715
Affibody receiv…
2015/12/02 10:39
Affibody receives clinical milestone from Daiichi Sankyo
Solna, Sweden, December 1, 2015.
Affibody AB announced today that it will receive a clinical milestone in connection with Daiichi Sankyo Company Limited’s (hereinafter Daiichi Sankyo; headquartered in Chuo Ward, Tokyo, TSE 4568) initiation of a Phase I study.
http://www.affibody.com/en/News/News/Affibody-receives-clinical-milestone-from-Daiichi-Sankyo/ -
No.658
Roche receives …
2015/11/27 12:40
Roche receives EU approval of Cotellic for use in combination with Zelboraf (PLX4032; Plexxikon) in advanced melanoma
Basel, 25 November 2015
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the European Commission has approved CotellicTM (cobimetinib) for use in combination with Zelboraf® (vemurafenib) for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation. The EU approval is based on data that showed Cotellic plus Zelboraf helped people with previously untreated BRAF V600 mutation-positive advanced melanoma live for more than a year without their disease worsening.
http://www.roche.com/media/store/releases/med-cor-2015-11-25.htm
Daiichi Sankyo …
2016/10/21 09:24
Daiichi Sankyo and Plexxikon SUSPEND Phase III Trial of Drug for Rare Tendon Cancer
By Mark Terry, BioSpace.com Breaking News Staff
Last Updated: October 20, 2016 @ 10:30am PT
http://www.biospace.com/News/daiichi-sankyo-and-plexxikon-suspend-phase-iii/436126